DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 15310.0
(-1.73%)
KRW 15310.0
(-1.73%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 405.04 Billion KRW | 7.96% |
| 2022 | 375.19 Billion KRW | 8.44% |
| 2021 | 345.99 Billion KRW | 3.59% |
| 2020 | 334.01 Billion KRW | 16.09% |
| 2019 | 287.71 Billion KRW | 21.45% |
| 2018 | 236.9 Billion KRW | 13.44% |
| 2017 | 208.83 Billion KRW | 14.41% |
| 2016 | 182.52 Billion KRW | 23.35% |
| 2015 | 147.97 Billion KRW | 15.82% |
| 2014 | 127.76 Billion KRW | 4.1% |
| 2013 | 122.72 Billion KRW | 15.63% |
| 2012 | 106.13 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 110.97 Billion KRW | 2.45% |
| 2024 Q1 | 108.31 Billion KRW | 5.03% |
| 2023 Q2 | 102.8 Billion KRW | 2.46% |
| 2023 FY | 405.04 Billion KRW | 7.96% |
| 2023 Q4 | 103.13 Billion KRW | 4.43% |
| 2023 Q3 | 98.76 Billion KRW | -3.93% |
| 2023 Q1 | 100.34 Billion KRW | 8.67% |
| 2022 Q4 | 92.33 Billion KRW | 1.17% |
| 2022 Q3 | 91.26 Billion KRW | -5.67% |
| 2022 Q2 | 96.75 Billion KRW | 2.03% |
| 2022 Q1 | 94.83 Billion KRW | 7.95% |
| 2022 FY | 375.19 Billion KRW | 8.44% |
| 2021 Q2 | 89.85 Billion KRW | 5.16% |
| 2021 Q1 | 85.44 Billion KRW | 1.69% |
| 2021 Q4 | 87.84 Billion KRW | 6.02% |
| 2021 Q3 | 82.85 Billion KRW | -7.79% |
| 2021 FY | 345.99 Billion KRW | 3.59% |
| 2020 Q2 | 84 Billion KRW | 6.33% |
| 2020 Q4 | 84.02 Billion KRW | -6.73% |
| 2020 FY | 334.01 Billion KRW | 16.09% |
| 2020 Q1 | 79 Billion KRW | 2.03% |
| 2020 Q3 | 90.08 Billion KRW | 7.23% |
| 2019 Q2 | 72.87 Billion KRW | 10.85% |
| 2019 FY | 287.71 Billion KRW | 21.45% |
| 2019 Q1 | 65.73 Billion KRW | 10.75% |
| 2019 Q4 | 77.43 Billion KRW | 4.04% |
| 2019 Q3 | 74.42 Billion KRW | 2.14% |
| 2018 Q2 | 61.92 Billion KRW | 14.02% |
| 2018 Q4 | 59.35 Billion KRW | -4.37% |
| 2018 Q3 | 62.07 Billion KRW | 0.24% |
| 2018 FY | 236.9 Billion KRW | 13.44% |
| 2018 Q1 | 54.3 Billion KRW | 2.55% |
| 2017 Q1 | 48.08 Billion KRW | 3.36% |
| 2017 Q4 | 52.95 Billion KRW | -1.7% |
| 2017 Q3 | 53.87 Billion KRW | -0.7% |
| 2017 Q2 | 54.25 Billion KRW | 12.82% |
| 2017 FY | 208.83 Billion KRW | 14.41% |
| 2016 FY | 182.52 Billion KRW | 23.35% |
| 2016 Q2 | 47.69 Billion KRW | 11.09% |
| 2016 Q1 | 42.92 Billion KRW | 4.58% |
| 2016 Q4 | 46.52 Billion KRW | 2.44% |
| 2016 Q3 | 45.41 Billion KRW | -4.76% |
| 2015 Q2 | 35.68 Billion KRW | 13.85% |
| 2015 Q1 | 31.34 Billion KRW | -0.72% |
| 2015 Q3 | 40.08 Billion KRW | 12.31% |
| 2015 Q4 | 41.04 Billion KRW | 2.41% |
| 2015 FY | 147.97 Billion KRW | 15.82% |
| 2014 Q3 | 33.36 Billion KRW | 2.31% |
| 2014 Q4 | 31.57 Billion KRW | -5.37% |
| 2014 FY | 127.76 Billion KRW | 4.1% |
| 2014 Q1 | 30.2 Billion KRW | -6.86% |
| 2014 Q2 | 32.61 Billion KRW | 7.96% |
| 2013 Q4 | 32.43 Billion KRW | 5.27% |
| 2013 FY | 122.72 Billion KRW | 15.63% |
| 2013 Q1 | 28.41 Billion KRW | -1.65% |
| 2013 Q2 | 31.06 Billion KRW | 9.33% |
| 2013 Q3 | 30.8 Billion KRW | -0.83% |
| 2012 FY | 106.13 Billion KRW | 0.0% |
| 2012 Q4 | 28.89 Billion KRW | -0.01% |
| 2012 Q3 | 28.89 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 82.98 Billion KRW | -388.089% |
| CMG Pharmaceutical Co., Ltd. | 43.7 Billion KRW | -826.813% |
| Celltrion Pharm, Inc. | 116.95 Billion KRW | -246.309% |
| Huons Global Co., Ltd. | 417.8 Billion KRW | 3.054% |
| Enzychem Lifesciences Corporation | 3.29 Billion KRW | -12198.258% |
| Humedix Co., Ltd. | 68.04 Billion KRW | -495.259% |
| Boditech Med Inc. | 76.7 Billion KRW | -428.052% |
| EuBiologics Co., Ltd. | 32.65 Billion KRW | -1140.213% |
| FutureChem Co.,Ltd | 758.27 Million KRW | -53316.539% |
| Huons Co., Ltd. | 285.93 Billion KRW | -41.653% |
| BNC Korea Co., Ltd. | 31.97 Billion KRW | -1166.625% |
| AptaBio Therapeutics Inc. | 78.49 Million KRW | -515884.929% |